Inclusion criteria: Metastatic non-squamous NSCLC with RET alterations. Documentation of locally assessed radiological disease progression while on or after last treatment.
Sponsor/Collaborator: Merck Sharp & Dohme LLC
Contact and Locations:
Study email: Trialsites@msd.com
Phone Number: 1-888-577-8839
Locations (U.S. and outside the U.S.): https://clinicaltrials.gov/study/NCT06074588#study-overview
Mechanism of action: Sacituzumab tirumotecan is an investigational trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC).
Phases: Phase 3
NCT Number: NCT06074588
Status: Recruiting
